Jarad Hayes connects biotech and pharma teams under FDA and pipeline pressure with the CROs and specialist operators who deliver — the day the pressure hits the record.
Public FDA, trial, and filing data, updated as it publishes — this is the market I watch.
- →FDA hits five online peptide sellers, including Peptide Partners and NuScience Peptides, with warning letters — unapproved semaglutide, tirzepatide, and retatrutide products cited as misbranded new drugs (FDA, Sep 2026)
- →Glycerol phenylbutyrate oral liquid, the generic Ravicti for urea cycle disorders, lands on FDA’s drug shortage list — Teva and Camber flag supply constraints on the only marketed strength (FDA, Sep 2026)
- →Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials of rap-cel and zola-cel — three deaths from immune effector cell-associated hemophagocytic syndrome trigger an eight-study clinical hold (Novartis, Sep 2026)
- →Novartis moves to shutter small-scale biologics production at its Kleinbasel site — up to 130 Basel roles at risk as lab work relocates to the main campus (Novartis, Sep 2026)
Sourced from FDA warning letters and shortages, sponsor announcements, and company disclosures.
No deal to point at yet — so here’s exactly what I put in motion.
- Flagged sponsor → operator who fixes it When a warning letter, a 483, or a trial setback lands, the clock starts. I put the right CRO or quality specialist in the room while it’s still a problem — not yet a consent decree.
- CRO / specialist → the sponsors who just learned they need you If you run trials, remediate quality systems, or rescue programs for a living, I bring you the sponsors the day their problem becomes public record.
Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.
What I see in this market that outsiders miss.